Durect Corp.

Felix Theeuwes, D.Sc. is Chairman, co-founder, and Chief Scientific Officer at DURECT Corporation, established in July of 1998 as a spinout from ALZA Corporation to focus on the development of pharmaceutical systems and products to treat chronic debilitating diseases and enabling biotechnology drugs. Dr. Theeuwes was with ALZA Corporation from 1970 until June 1999 holding positions directing research, technology development, and product development for a variety of controlled drug delivery systems. His work led to the product introduction of the ALZET® mini osmotic pump series for animal research, and the OROS® systems series of products. He directed research in transdermal research and development, initiated the electrotransport/iontophoresis program, and initiated the DUROS® osmotic implant program. He holds more than 210 U.S. patents covering these systems and published more than 80 articles and book chapters. In 1980 Dr. Theeuwes was named Inventor of the Year by the Peninsula Patent Law Association. In 1983 he was the recipient of the Award for the Advancement of Industrial Pharmacy. He was the Busse Lecturer at the University of Wisconsin in 1981, and in 1985 the Third Annual Sidney Riegelman Lecturer at the University of California, San Francisco. He is a Fellow of the American Association of Pharmaceutical Scientists. In 1993 he became the first recipient of ALZA Corporation's Founder's Award. In 1993 Dr. Theeuwes completed the Stanford Executive Program (SEP). He received his undergraduate and graduate education in physics at the University of Leuven (Louvain), Belgium, with a D.Sc. degree in 1966. From 1966 to 1970 he served as a post-doctoral fellow and visiting research assistant professor in the Department of Chemistry, University of Kansas.

Matthew J. Hogan, joined DURECT from Ciphergen Biosystems, Inc., where he was the Chief Financial Officer from 2000 to 2006 and a consultant from March 2006. Prior to joining Ciphergen, Mr. Hogan was the Chief Financial Officer at Avocet Medical, Inc. from 1999 to 2000. From 1996 to 1999, Mr. Hogan was the Chief Financial Officer at Microcide Pharmaceuticals, Inc. From 1986 to 1996, he held various positions in the investment banking group at Merrill Lynch & Co., most recently as a Director focusing on the biotechnology and pharmaceutical sectors. Mr. Hogan holds a B.A. in economics from Dartmouth College and an M.B.A. from the Amos Tuck School of Business Administration.

Peter J. Langecker, M.D., Ph.D. Dr. Langecker has been the Chief Medical Officer since May 1, 2006 at DURECT Corporation. Dr. Langecker joins DURECT from Intarcia Therapeutics, Inc. where he served as Chief Medical Officer and Vice President Clinical Affairs. He received his doctorate in medical sciences from the Ludwig-Maximilians University in Munich. He trained in hematology and oncology and has extensive experience in developing drugs and biological products in both Europe and the United States. Dr. Langecker was formerly based in Switzerland where he developed a variety of products for Novartis. He came to the U.S. as a Director in Clinical Research for Schering-Plough and as Vice President, Clinical Research for Coulter Pharmaceuticals. More recently he served as Vice President of Clinical Affairs for SUGEN, Inc. until its merger with Pharmacia & Upjohn. Dr. Langecker has also served as a Director for Xcyte Therapies based in Seattle, WA.

Mr. McCracken has over 15 years of professional experience in the biopharmaceutical field, including the provision of legal advice and guidance in international intellectual property matters with a special emphasis in the area of patenting pharmaceuticals, vaccines, biotechnology and medical/analytical devices, and the licensing and transacting of technologies in those areas. Prior to joining DURECT, Mr. McCracken held positions as Senior Legal Counsel and Vice President, Intellectual Property, at PowderJect Pharmaceuticals in Fremont, California and in Oxford, United Kingdom from 1998 to 2004. From 1994 to 1998, he was engaged in private law practices at the biotech patent boutiques of Reed & Robins and Robins & Associates in Palo Alto and Menlo Park, California, respectively. In addition, from 1988 to 1990 Mr. McCracken held various research, development and production positions at several biotech start-ups in the San Diego area, and at the Research Institute of Scripps Clinic in La Jolla, California. Mr. McCracken received his undergraduate degree in Microbiology from the University of California, San Diego, and his Juris Doctorate from Santa Clara University School of Law. Mr. McCracken is also registered to practice with the U.S. Patent and Trademark Office, and is a member of the State Bar of California.

Dr. Mendenhall has over 30 years of pharmaceutical experience covering areas such as research, manufacturing and pharmaceutical operations. Prior to joining DURECT, during 1979 to 1997, Dr. Mendenhall served in a variety of roles for Hoffmann-La Roche Inc./Syntex, including in the areas of manufacturing, quality assurance, finance, planning and facilities, as well as provided technical assistance and support to Syntex Global Operations for marketed products and new product launches. Most recently prior to her joining DURECT, Dr. Mendenhall was an independent consultant for various pharmaceutical companies for in-house and outsourcing of pharmaceutical manufacturing, including development of manufacturing strategies and plans and development and training of personnel. Dr. Mendenhall received a Pharm D. degree from the University of California San Francisco, and is a member of the American Association of Pharmaceutical Scientists, the American Pharmaceutical Association and the Society of Cosmetic Chemists.

Jean I. Liu has served as Senior Vice President of Legal and General Counsel since March 2003. Previously, Ms. Liu served as our Vice President of Legal and General Counsel from February 1999 to March 2003 and our Vice President of Legal from October 1998 to February 1999. Prior to that, Ms. Liu worked as an attorney at Venture Law Group, a law firm, from May 1997 to October 1998. Ms. Liu worked as an attorney at Pillsbury Madison & Sutro LLP, a law firm, from September 1993 to May 1997. Ms. Liu received a B.S. in Cellular & Molecular Biology from University of Michigan, an M.S. in Biology from Stanford University and a J.D. from Columbia University School of Law.

Dr. Yum joined DURECT in 1999. Since then, he has continuously been involved in the application of several of DURECT's platform technologies such as DUROS®, SABER® and DURIN®. Su IL's significant contributions have played a huge role in the development of various parenteral and oral drug delivery systems that are based on these DURECT technologies. Prior to joining DURECT, Dr. Yum served as Senior Technical Advisor at Amira Medical in Scotts Valley, California, where he participated in the development of a pain-free blood glucose detector called AtLast®. Prior to joining Amira, he held a number of senior positions in project management and engineering at Alza Corporation ("Alza"). His contributions at Alza include the development of a number of Alza's enabling technologies and commercial products, most notably transdermal patch products such as, Nicoderm® nicotin and Duragesic® fentanyl systems. Other products include; Travenol Infusor®, which Alza licensed to Baxter, and ALZET® osmotic pumps, used for experimental research in laboratory animals. His fundamental insight into mass transport phenomena and product design were instrumental to his success in exploratory research, and development activities at Alza. Dr. Yum earned his Ph.D. degree in Chemical Engineering from the University of Minnesota, and completed a Post-doctoral research in Biomedical Engineering at the University of Utah. He has more than 40 scientific publications and is the holder of more than 60 U.S. and foreign patents. Dr. Yum is a Fellow of the AAPS.

Dr. Miksztal has over 18 years of pharmaceutical product development experience. He joined DURECT in March 2000 as Senior Director of Pharmaceutical Development, and in October 2000 was promoted to Executive Director. Prior to joining DURECT, Dr. Miksztal was the Associate Director of the Pharmaceutical Analysis Department at Oread Laboratories from 1996 to 2000, a Senior Scientist in Pharmaceutical Research at Roche Bioscience from 1995 to 1996, and a Scientist in the Preformulation and Pharmaceutical Analysis Departments at Syntex Research from 1987 to 1995. Dr. Miksztal earned his Ph.D. degree in Chemistry from Rutgers University, and completed an NIH postdoctoral research fellowship in the Chemistry Department at the University of California, San Diego. He has numerous scientific publications and is the inventor of several U.S. and foreign patents.

Charlotte R. Rogers. Ms. Rogers has over 20 years of pharmaceutical business development experience specializing in therapeutics, diagnostics, research reagents, and genomic technologies. Prior to joining DURECT, Ms. Rogers was the Vice President of Business Development for NuGEN Technologies. From 1999 to 2001, Ms. Rogers was a member of the business development team at IntraBiotics Pharmaceuticals, most recently as Senior Director of Business Development. From 1995 to 1999, Ms. Rogers was Director of Business Development for Elan Pharmaceuticals. From 1989 to 1995, Ms. Rogers served in a variety of roles for Hoffmann-La Roche Inc./Syntex, including commercial development and product life-cycle planning for central nervous system, anti-inflammatory and gastrointestinal products. Ms. Rogers earned a B.S. in Biology from the University of Santa Clara and holds an M.B. A. from the University of Santa Clara.

Mr. Guy will be responsible for the Engineering group in Cupertino as well as Facilities and Environmental Health & Safety for the corporation. For the last 11 years, Mr. Guy was employed at ALZA Corporation, where his last position was Executive Director of Materials Management and Environmental Health & Safety. In this position, he led functional teams with diverse requirements, including environmental health and safety, materials and distribution, and conducting supplier assessments. Prior to ALZA, Mr. Guy spent 11 years at Syntex as the Director of Corporate Industrial Health & Safety. Mr. Guy received his B.S. and M.S. degrees in Mechanical Engineering from Kansas State University. He was also in the Air Force, where he spent time as a Bioenvironmental Engineer.

Jian Li has served as our Vice President of Finance and Corporate Controller since December 2003. Previously, Ms. Li served as our Corporate Controller from April 2001 to December 2003, Assistant Controller from December 2000 to April 2001 and our Accounting Manager from March 2000 to December 2000. Prior to joining DURECT, she held various positions at Elan Pharmaceuticals in California and GTE Hawaiian Telephone in Honolulu, Hawaii in the roles of Financial Analyst, Accountant and Marketing Analyst. Ms. Li holds an M.B.A. from the University of Hawaii at Manoa. She is also a Certified Public Accountant and a member of American Institute of Certified Public Accountants.

John W. Gibson, B.S., Vice President, Birmingham Operations and Principal Scientist, has over 30 years of pharmaceutical product development experience involving biodegradable excipients and injectable, long-acting formulations. Mr. Gibson joined DURECT in 2001 as Executive Director of Product Development and assumed management responsiblity for DURECT’s Birmingham operations in 2005. Prior to joining DURECT, from 1974 through 2000, Mr. Gibson held a variety of technical and management positions with Southern Biosystems, Eastman Chemical Company, Eli Lilly and Company, and Southern Research Institute. Mr. Gibson received his B.S. and M.S. in Chemistry from the University of Alabama at Birmingham. He has numerous scientific publications and is the inventor of several U.S. and foreign patents.

Michael H. Arenberg leads business development for DURECT Corporation. Since joining DURECT in 1999, Mr. Arenberg has held a variety of positions with increasing responsibilities in general management, sales & marketing and business development where he has been responsible for a number of significant partnering deals. Prior to joining DURECT, Mr. Arenberg co-founded IntraEAR, Inc., a drug delivery medical device company in 1996 and served as the company’s Vice President of Sales, Marketing and Business Development until the company was sold to DURECT in 1999. Mr. Arenberg holds an M.B.A. from the Leavey School of Business at Santa Clara University and a J.D. from the University of Denver.

Nacer E. Dean Abrouk. Prior to joining DURECT, Dr. Abrouk was the Director of Statistics for ALZA Corporation, a Johnson & Johnson subsidiary, where he was responsible since January 2006 for overall statistical aspects of product development for worldwide regulatory submissions spanning several therapeutic areas, including pain management, oncology and urology. His most recent regulatory submissions include Dapoxetene, OROS Hydromorphone and IONSYS Fentanyl. From 2001 to 2005, Dr. Abrouk held various positions at Amgen Inc., most recently as a Senior Manager in Nephrology and Oncology, where he was responsible for the design and analysis of Phase 3 and 4 clinical studies. In addition, from 1992 to 2001, Dr. Abrouk held various positions at public and private companies, providing consultative services on statistical data analysis, data management, and report writing. Clients included Eli Lilly, Parke-Davis, Biomet Inc. and the Terre Haute Medical Laboratory. Dr. Abrouk received his undergraduate degree in Mathematics and Computer Science Microbiology from Constantine University, and his M.S. and Ph.D. in Statistics from Michigan State University.

John Middleton, PhD, Vice President, Chief Science Officer, brings a wealth of experience in leading technical and operational teams in polymer manufacture and in the development of drug delivery products. He has been synthesizing biodegradable polymers since the early 1980s. As the Vice President and Technical Director of Birmingham Polymers (BPI), he directed the day-to-day operations of BPI from 1996-2001. During that time he was involved in the synthesis of over 600 batches of polymer and the commercialization of five products. As a Director of Product Development at Durect from 2001-2003, Dr. Middleton lead technical teams on programs at the both bench and clinical level. Previous to his roles in Birmingham Polymers and Durect, Dr. Middleton worked in the industrial fiber business for Monsanto (now Solutia). Dr. Middleton has published 18 articles in scientific and trade journals and holds two patents. He received his doctorate in Polymer Science from the University of Southern Mississippi.

Terrence F. Blaschke, MD, is Professor of Medicine and Molecular Pharmacology (Active Emeritus) at Stanford University, Adjunct Professor of Biopharmaceutical Sciences at UCSF and Adjunct Professor of Medicine at Indiana University. Dr. Blaschke received his medical degree from Columbia University and did his residency training in Internal Medicine at UCLA. Following fellowship training in Clinical Pharmacology at the University of California, San Francisco, he joined the faculty at Stanford University in 1974. Dr. Blaschke is a past president of the American Society for Clinical Pharmacology and Therapeutics. He is the recipient of the Rawls-Palmer award and the Henry W Elliott award from ASCPT. He has been a consultant and past Chair of the Generic Drugs Advisory Committee of the US FDA and is currently a member of the Nonprescription Drugs Advisory Committee. He chaired the Drug Utilization Review Panel of USP from 1995-2000. He is also a consultant to a number of pharmaceutical firms and served as a Director of Therapeutic Discovery Corporation of Palo Alto and Crescendo Pharmaceuticals, in Mountain View, California. He was a member of the AIDS Clinical Trials Group (ACTG) at its inception, and has served as chair of the Pharmacology Committee and a member of the Executive Committee of the ACTG. His research has been primarily in the area of clinical investigation, with a focus on the clinical pharmacology of drugs used in patients with HIV infection and an emphasis on modeling exposure-response relationships. His involvement in clinical trials and with the pharmaceutical industry has also led to a strong interest in approaches to improve the efficiency of the drug development process. Dr. Blaschke has over 170 original publications in peer reviewed journals and is an Associate Editor of the Annual Review of Pharmacology and Toxicology.